RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 10.32

Change

+0.05 (+0.49)%

Market Cap

N/A

Volume

3.40K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

+0.03 (+0.28%)

USD 0.99B
SOXS Direxion Daily Semiconductor B..

+1.98 (+10.59%)

USD 0.76B
PSQ ProShares Short QQQ

+0.30 (+0.78%)

USD 0.65B
SPXU ProShares UltraPro Short S&P50..

+0.25 (+1.06%)

USD 0.55B
SDOW ProShares UltraPro Short Dow30

+0.08 (+0.60%)

USD 0.32B
YANG Direxion Daily FTSE China Bear..

+0.12 (+3.41%)

USD 0.22B
DOG ProShares Short Dow30

+0.04 (+0.15%)

USD 0.17B
RWM ProShares Short Russell2000

+0.03 (+0.16%)

USD 0.16B
SPDN Direxion Daily S&P 500® Bear ..

+0.03 (+0.27%)

USD 0.14B
DUST Direxion Daily Gold Miners Ind..

+0.13 (+2.73%)

USD 0.11B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2,668.15% 40% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 2,668.15% 40% F 99% N/A
Trailing 12 Months  
Capital Gain 2,215.95% 40% F 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 2,215.95% 40% F 98% N/A
Trailing 5 Years  
Capital Gain 715.00% 44% F 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 715.00% 44% F 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 36.37% 38% F 91% A-
Dividend Return 37.42% 38% F 90% A-
Total Return 1.06% 55% F 24% F
Risk Return Profile  
Volatility (Standard Deviation) 368.17% 62% D 3% F
Risk Adjusted Return 10.16% 38% F 29% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.